(Information from the subscriber company)
Korea, March 13, 2023.
Macrogen has completed the installation of its first NovaSeq X Plus at the Genome Center in Korea and plans to install further units this year, a total of five computers with the company’s subsidiaries in Korea, Japan, and Europe. With this collaboration, Macrogen shows its great interest in the business and will be focused on rapid and accurate sequencing of large genomes.
Macrogen, a global company specializing in genome sequencing, completed the installation of NovaseqX Plus on April 6, the first company to adopt NovaSeq X Plus, a high-precision whole genome sequencing system developed by US-d Illumina in Korea.
With the NovaSeq X Plus fully installed, Macrogen will be able to operate with the most innovative system. After this first installation at the Korean Genome Center, Macrogen will continue to install four units in its global subsidiaries, including in Japan and Europe, as well as at Psomagen, its US partner company, for five. NovaSeq X Plus equipment. in his labs later this year.
Featuring the latest in new technologies, NovaSeq X Plus has dramatically increased annual genome sequencing from approximately 8,000 to 20,000 complete genomes, representing a 2.5-fold increase. Macrogen plans to dramatically increase its throughput with the help of NovaSeq X Plus, which will serve as a growth engine for sequencing business.
Macrogen Vice President Eungryong Lee is very proud that Macrogen is one of the first companies in the market to offer its customers the latest sequencing technologies represented by NovaSeq X Plus. This will dramatically increase Macrogen’s sequencing capabilities and in turn the company’s growth and genome sequencing business. Our goal is to not only strengthen our position as the main market leader in Korea, but also have a good position in the global market, so that we can accelerate revenue growth both in Korea and abroad.
Rob McBride, Illumina’s general manager in Korea, notes that Macrogen is one of Illumina’s most prominent global partners and the first in Korea to receive NovaSeq X. Through this collaboration, Illumina and Macrogen look forward to leveraging the benefits that NovaSeq X can bring. customers
Among these, last September, Macrogen became the only Korean company to join Illumina’s brilliant four global partners in launching NovaSeq X, whose other members include the Broad Institute, deCODE Genetics and Regeneron Genetics.
The NovaSeq X engine offers a dramatic improvement over existing sequencers in terms of speed, scale, accuracy and sustainability, it also offers significant improvement in the following areas:
• 2 times more speed and up to 3 times more accurate.
2.5 times the performance, thanks to the high resolution perspective and ultra-high density flow cells.
• Fully automated, high-precision secondary analysis with 5x data compression loss.
• Reduced packaging waste with heat-stable reagents.
The new technology is expected to provide a major breakthrough in the development of genomic medicine, including cancer treatments and genetic disease research, promoting improvement in the quality of human health.
Contact name: Ana
Contact details: Ana
Contact phone: 635832160